Litcius/Paper detail

Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities

Monica Margoni, Francesca Rinaldi, Paola Perini, Paolo Gallo

2021Frontiers in Neurology32 citationsDOIOpen Access PDF

Abstract

Treatment of pediatric-onset multiple sclerosis (POMS) has been tailored after observational studies and data obtained from clinical trials in adult-onset multiple sclerosis (AOMS) patients. There are an increasing number of new therapeutic agents for AOMS, and many will be formally studied for use also in POMS. However, there are important efficacy and safety concerns regarding the use of these therapies in children and young adults. This review will discuss the current state of the art of POMS therapy and will focus on the newer therapies (oral and infusion disease-modifying drugs) and on those still currently under investigation.

Topics & Concepts

Multiple sclerosisObservational studyClinical trialMedicineIntensive care medicineInternal medicinePsychiatryMultiple Sclerosis Research StudiesPolyomavirus and related diseasesRNA Interference and Gene Delivery
Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities | Litcius